Targeted trial aims to help underrepresented patients with serious transplant complication
Disease control
Terminated
This study aimed to test the safety and effectiveness of an oral drug called belumosudil for people with chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell or bone marrow transplant. It specifically focused on recruiting Black, African American, A…
Phase: PHASE2 • Sponsor: Kadmon, a Sanofi Company • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC